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Abstract 
Background–Exenatide extended-release (-ER) is a glucagon-like peptide-1 analogue that 
increases insulin secretion, inhibits glucagon secretion and induces satiation in humans with type 
2 diabetes mellitus. The use of exenatide-ER is safe and stimulates insulin secretion in healthy 
cats. 
Objectives–To assess the safety of exenatide-ER and its effect on body weight, remission and 
metabolic control in diabetic cats receiving insulin and a low-carbohydrate diet. 
Animals–Thirty client-owned cats with newly diagnosed diabetes mellitus. 
Methods–Prospective placebo-controlled clinical trial. Cats were alternately allocated to receive 
exenatide-ER or 0.9% saline, administered subcutaneously, once per week. Both groups were 
treated with insulin glargine and received a low-carbohydrate diet. Exenatide-ER was 
administered for 16 weeks, or in cats that achieved remission it was given for 4 weeks after 
discontinuing insulin therapy. Remission was defined as euglycemia ≥4 weeks after discontinuing 
insulin therapy. Nonparametric tests were used for statistical analysis. 
Results–Cats treated with exenatide-ER had transient adverse signs that included reduced 
appetite (60% vs. 20% in controls) and vomiting (53.3% vs. 40%). Body weight increased 
significantly in the placebo group (P=0.002), but not in cats receiving exenatide-ER. Cats treated 
with exenatide-ER achieved remission or good metabolic control in 40% or 88.9%, respectively, 
whereas in the control cats the percentage were 20% or 58.3% (P=0.427 and P=0.178, 
respectively). 
Conclusion and clinical importance–Exenatide-ER is safe in diabetic cats, does not result in 
weight gain and may improve the rate of remission and metabolic control, although further 
studies in large cohorts are required.
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Incretins, such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic 
polypeptide (GIP), have been the focus of recent studies because of their beneficial role in 
glucose homeostasis. Incretins are gastrointestinal hormones released in response to food intake 
that increase insulin secretion in various species and has shown to stimulate pancreatic β-cell 
proliferation in rodents.1,2 Additionally, they inhibit glucagon secretion, slow gastric emptying, 
induce satiation and promote weight loss.2 However, the half-life of GLP-1 and GIP is only a few 
minutes because they are rapidly cleaved by dipeptidylpeptidase-4 (DPP-4).2,3 Incretin-based 
therapies have been developed for humans with type 2 DM; they include GLP-1 receptor 
analogues that are resistant to rapid degradation of DPP-4, such as liraglutide and exenatide or 
exenatide-ER, and DPP-4 inhibitors, such as sitagliptin and vildagliptin, which reduce the 
degradation of endogenous GLP-1. Exenatide-ER, which requires only once weekly dosing in 
human type 2 diabetic patients, was more efficacious in reducing glycated hemoglobin, improved 
metabolic control and promoted weight loss more often than DPP-4 inhibitors.4 Exenatide-ER 
resulted in greater improvements in metabolic control, induced nausea and vomiting less 
frequently than exenatide which has to be given twice daily, although injection site irritations 
were more common.5,6 Furthermore, exenatide-ER is currently considered an effective second-
line treatment in humans with type 2 DM because it rarely induces hypoglycemia when used as 
monotherapy.4-6 
To date, the biology and effects of incretins have been investigated only in healthy cats. In one 
study, GLP-1 increased after oral glucose administration.7 DPP-4 inhibitors were shown to lower 
plasma glucagon and to enhance insulin secretion in cats.8,9 Administration of exenatide, 
exenatide-ER or liraglutide resulted in glucose-dependent insulin secretion and a pronounced 
effect on insulin secretion during normoglycemia, and a reduction in body weight occurred after 
the administration of exenatide and liraglutide in cats.10-13 A recent comparison of incretin-based 
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treatments in cats showed that exenatide and exenatide-ER have more pronounced effects on 
insulin secretion than sitagliptin (a DPP-4 inhibitor).14 Furthermore, exenatide-ER was 
considered a better option than exenatide or sitagliptin because it is administered only once 
weekly and has fewer side effects.14 
The goal of the present study was to determine whether administration of exenatide-ER is safe in 
newly diagnosed diabetic cats treated with insulin glargine and a low-carbohydrate diet. In 
addition, the effect of exenatide-ER on body weight, remission rate and metabolic control were 
investigated. 
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Materials and Methods 
Animals 
This prospective clinical trial used newly diagnosed diabetic cats admitted from January 2013 to 
January 2015. The diagnosis of DM was based on clinical signs and laboratory tests.15 Cats were 
excluded if they had received insulin or other antidiabetic medication for longer than 4 weeks 
before admission, if glucocorticoids or progestagens had been given during the previous 3 
months or if a concurrent disease such as e.g. renal failure, gastrointestinal disorder, heart 
disease, an other endocrinopathy or neoplasia was diagnosed. Diabetic cats with ketoacidosis or 
pancreatitis were included in the study if clinical signs resolved and their general condition 
improved within 48 hours of treatment. All cats underwent a thorough evaluation including 
physical examination, blood measurements and urinalysis (Table 1), blood pressure measurement, 
abdominal and thoracic radiography and abdominal ultrasonography. A cut-off value of >5.3 µg/L 
was used for Spec fPL concentration.a For 1,2-o-dilauryl-rac-glycero-3-glutaric acid-(6′-
methylres-orufin) ester (DGGR)-lipase activity, the cut-off was set at >26 U/L based on the 
interval previously established in healthy cats (8-26 U/L).16 For insulin-like growth factor 1 (IGF-
1) a cut-off value of >1000 ng/mL was used in accordance to laboratory guidelines.b The 
experiment was approved by authorities in Switzerland (permission: 122/2011, 118/2014) and in 
Italy (permission: 16/79/2014, CE17/02/14). Informed consent was provided by owners. 
 
Randomization and treatment 
Enrolled cases were alternately assigned to 1 of 2 treatment groups. Both groups received insulin 
glarginec and a low-carbohydrate dietd. The initial insulin dosage was 1.0 IU, q12h, in cats 
weighing <4 kg and 1.5-2.0 IU, q12h, in cats ≥4 kg. One group received exenatide-ERe (200 
µg/kg) and the other 0.33 mL of 0.9% saline solution (placebo); both treatments were 
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administered subcutaneously, once weekly. Owners were taught how to prepare and inject the 
exenatide-ER or placebo, but were unaware of the treatment group. If owners found this task 
problematic, a veterinarian administered the weekly injections. 
Exenatide-ER was administered for 16 weeks or in cats that achieved diabetic remission, it was 
given for 4 weeks after discontinuing insulin therapy.  
 
Follow-up 
Successive follow-up evaluations were scheduled 1, 3, 6, 10 and 16 weeks after starting 
exenatide-ER or placebo. Each evaluation included assessment of clinical signs, physical 
examination, blood analysis (Table 1) and generation of a glucose curve. Owners were instructed 
to perform home-monitoring of blood glucose concentrations every 1-2 weeks starting 3 weeks 
after enrollment. To complete all curves, capillary blood glucose concentrations were measured 
every 2 hours for 8-12 hours using a validated portable blood glucose meter.17 The insulin dosage 
was adjusted based on clinical signs and results of physical examination, glucose curves and 
serum fructosamine concentration; the goal was to resolve clinical signs of DM and to obtain 
curves with blood glucose ranging between 80-270 mg/dL and fructosamine concentrations 
between 350-450 µmol/L.18 In cats that achieved remission, the insulin dose was decreased in 
increments of 0.5 IU per treatment, once weekly. The last dosage before insulin was discontinued 
was 0.5 UI once daily, for at least 1 week. The frequency, onset and duration of remission were 
recorded in both groups. The rate of metabolic control was evaluated at the end of the study. 
Criteria used to define remission and good metabolic control are explained in Table 2. 
The frequency of hypoglycemia, defined as a blood glucose curve value ≤65 mg/dL, was 
determined. If owners observed clinical signs compatible with hypoglycemia (increased appetite, 
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restlessness, weakness, unsteady gait, loss of consciousness or cramps), they were instructed to 
measure capillary blood glucose concentration and to offer food or administer honey.  
The median insulin dose per kg per day given during the study period was calculated for each cat. 
Two calculations were done; in one of them the phases of remission were excluded, in the other 
one the phases of remission were included. 
 
Statistical analysis 
Data are presented as median and ranges. Distribution of sex and breed, frequency of cases 
treated with antidiabetic medications before inclusion, and frequency of ketoacidosis recorded at 
admission were compared between cats receiving exenatide-ER and placebo using Fisher’s exact 
test. The same test was used to compare the frequency of side effects and of hypoglycemic 
episodes, the rate and onset of remission and the rate of good metabolic control between groups. 
Differences between groups for age, body weight and laboratory results recorded at admission 
and for daily insulin dosage given over the 16-week study period were analyzed using the Mann-
Whitney U-test. The same test was used to compare concentrations of fructosamine, Spec fPL, 
DGGR-lipase and creatinine concentrations between groups at each follow-up evaluation. Within 
each group, differences in body weight, body condition score (BCS)f and fructosamine, Spec fPL, 
DGGR-lipase and creatinine between baseline and the end of the study were investigated using 
the Wilcoxon signed rank test. A commercial softwareg was used. Significance was set at P<0.05. 
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Results 
Animals 
Of 52 cats with newly diagnosed DM admitted during the study period, 30 cats fulfilled the 
inclusion criteria and were enrolled. Each treatment group consisted of 15 cats. There were no 
significant differences between the two groups with regard to age, body weight, distribution of 
breeds or sex or frequency of cats previously treated with anti-diabetic medication (Table 3). 
On admission, 9 cats had ketoacidosis, which resolved within 1-2 days of treatment; 3 were 
allocated to the exenatide-ER group and 6 to placebo. The frequency of ketoacidosis did not 
differ between groups (P=0.427). None of the cats died during the study. 
 
Side effects 
Side effects recorded in cats treated with exenatide-ER and placebo are documented in Table 4. 
Most of the gastrointestinal side effects were self-limiting. In 1 cat that vomited 4 weeks after 
enrollment, the referring veterinarian prescribed cimetidine. Vomiting subsided, but recurred in 
week 10, at which time exenatide-ER treatment was discontinued. The frequency of side effects 
did not differ between groups (Table 4). 
Skin lesions were not seen at the injection site of exenatide-ER or placebo. One cat treated with 
exenatide-ER developed non-pruritic histiocytic panniculitis, which was deemed unrelated to 
drug administration because it was 5-10 cm away from the injection site. 
 
Hypoglycemia 
Fourteen of 15 cats (93.3%) treated with exenatide-ER and 12 of 15 cats (80%) treated with 
placebo had episodes of biochemical hypoglycemia based on blood glucose curves; the frequency 
of hypoglycemic episodes did not differ between groups (P=0.598). Median glucose 
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concentration during hypoglycemia was 47 mg/dL (range: 25-65) in the exenatide-ER group and 
50 mg/dL (range: 29-63) in the placebo group. Most of the cats did not have clinical signs of 
hypoglycemia. However, 2 cats with biochemical hypoglycemia in the exenatide-ER group had 
clinical signs compatible with hypoglycemia, including reduced appetite, vomiting and lethargy. 
Episodes of hypoglycemia were observed more often in weeks 6 and 7 in the exenatide-ER group 
and in weeks 8 to 12 in the placebo group (Figure 1). 
 
Laboratory results and insulin dosage administered during the study 
Baseline results of a complete blood count, biochemical profile, urinalysis and blood pressure 
measurement did not differ between groups (Table 5); positive urine culture was seen in 1 (6.7%) 
cat in the exenatide-ER group and in 2 (13.3%) in the placebo group.  
In cats treated with exenatide-ER, the median fructosamine concentration was 620 µmol/L 
(range: 402-883) at baseline and 361 µmol/L (range: 267-483) after 16 weeks. In the placebo 
group, the median fructosamine concentration was 582 µmol/L (range: 438-878) at baseline and 
377 µmol/L (range: 256-718) after 16 weeks. A significant decrease in serum fructosamine 
concentration was observed in both groups (P=0.001, each). Differences between groups were 
not identified at any time point. 
In both groups, at the end of the study concentrations of Spec fPL [exenatide-ER: 1.8 µg/L 
(range: 0.6-25.4); placebo: 2.15 µg/L (range: 1.0-14.3); P=0.115, P=0.650, respectively] and 
DGGR-lipase [exenatide-ER: 19 U/L (range: 10-89); placebo: 18.5 U/L (range: 12-56); P=0.372, 
P=0.479, respectively] did not differ to baseline concentrations (Table 5). There was no 
difference in the concentration of either enzyme between groups at any time point (Figure 2). In 
the exenatide-ER group, baseline Spec fPL concentration was higher than normal in 3 (20%) cats 
and remained increased throughout the study. The Spec fPL was higher than normal at 16 weeks 
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in 1 of the 12 (8.3%) cats with a baseline Spec fPL concentration ≤5.3 µg/L. In the placebo 
group, the baseline Spec fPL concentration was higher than normal in 5 (33.3%) cats, and it 
remained increased throughout the study in 2 of them. Two of 10 (20%) cats with initial Spec fPL 
concentrations ≤5.3 µg/L had higher than normal Spec fPL concentrations after 16 weeks (Figure 
2A). The concentration of serum DGGR-lipase was measured in 23 of the 30 cats. In the 
exenatide-ER group, baseline serum DGGR-lipase concentration was higher than normal in 4 of 
11 (36.4%), and remained elevated throughout the study in 3 of them. In the placebo group, 
baseline serum DGGR-lipase concentration was higher than normal in 5 of 12 (41.7%) cats, and 
remained elevated throughout the study in 4 of them (Figure 2B). The concentration of serum 
DGGR-lipase did not increase by the end of the study in any of the cats that had normal baseline 
concentrations. Cats with increased Spec fPL or DGGR-lipase concentrations did not have 
obvious clinical signs or ultrasonographic evidence of pancreatitis. 
In the exenatide ER group concentration of creatinine was slightly above the reference range in 1 
(6.7%) cat at baseline but it normalized by the end of the study. Creatinine significantly increased 
from baseline (Table 5) to the end of the study in both groups [exenatide-ER: 1.4 mg/dL (range: 
1.1-1.9); placebo: 1.4 mg/dL (range: 1.0-1.9); P=0.012, P=0.005, respectively], although in only 
1 cat per group it slightly exceeded the reference range. Differences between groups were not 
identified at any time point. 
The median concentration of IGF-1 was 372 ng/mL (range: 227-1163 ng/mL) in the exenatide-
ER group and 405 ng/mL (range: 167-1041 ng/mL) in the placebo group. There was no 
significant difference between groups (P=0.408). One cat of each group had an IGF-1 
concentration >1,000 ng/mL, but neither developed clinical signs of acromegaly, and both 
achieved remission at week 8 and 10, respectively. Computed tomographic examination of the 
head of 1 of the 2 cats revealed an unremarkable pituitary gland. 
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The median insulin dosage administered to cats receiving exenatide-ER or placebo during the 
study did not differ [exenatide-ER: 0.41 IU/kg/day (range: 0.11-0.88); placebo: 0.38 IU/kg/day 
(range: 0.22-1.5); P=0.663] (Figure 3). The median insulin dose administered during the study in 
cats also did not differ if phases of remission were not excluded from the calculation [exenatide-
ER: 0.36 IU/kg/day (range: 0.07-0.88); placebo: 0.33 IU/kg/day (range: 0.13-1.5); P=0.494]. 
 
Body weight 
In the exenatide-ER group, body weight decreased in 6 cats (40%) [median: -0.22 kg (range: -
0.14 to -0.64)], increased in 8 (53.3%) [median: +0.89 kg (range: +0.20 to +1.50)] and did not 
change in 1 (6.7%) during the study period. In the placebo group, body weight decreased in 2 cats 
(13.3%) [median: -0.28 kg (range: -0.2 to -0.35)] and increased in 13 (86.7%) [median: +0.76 kg 
(range: +0.18 to +2.00)]. Overall, median body weight increased in both groups during the study; 
the increase was significant in the placebo group (P=0.002), but not in exenatide-ER treated cats 
(P=0.084) (Figure 4). BCS increased significantly in the placebo group (P=0.002), but not in the 
exenatide-ER group (P=0.058) (BCS are provided in Table 6). 
 
Remission and metabolic control 
Remission of DM was achieved in 6 (40%) cats treated with exenatide-ER and in 3 (20%) cats 
treated with placebo (P=0.427). All cats that achieved remission had no relapse of DM until the 
study end. In the exenatide-ER group, remission occurred 10-14 weeks (median: 11 weeks) after 
initiation of treatment, and in the placebo group, 8-10 weeks (median: 10) after initiation of 
treatment; the onset of remission did not differ between groups (Table 7). Good metabolic control 
was obtained in 8 of 9 (88.9%) non-remission cats in the exenatide-ER group, and in 7 of 12 
(58.3%) non-remission cats in the placebo group (P=0.178). If cats in remission were grouped 
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together with those achieving good metabolic control, 14 of 15 (93.3%) diabetic cats treated with 
exenatide-ER had remission or good metabolic control compared with only 10 of 15 (66.7%) 
diabetic cats treated with placebo (P=0.169).
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Discussion 
In humans with type 2 DM, exenatide-ER administration is generally well tolerated, although 
transient and mild gastrointestinal side effects are frequently reported.5,6,20 Gastrointestinal side 
effects of exenatide-ER have been described recently in healthy cats,14 and were the most 
common side effect in the present study. They were usually mild and self-limiting which was an 
in agreement with findings in other species.3 Although the etiology is not fully understood, 
reduced gastric emptying caused by GLP-1 analogues might be partially responsible.2,21 
Increased duration of sleeping and hiding in dark areas were frequently reported by owners of 
diabetic cats treated with exenatide-ER, but these behaviors were observed in the placebo group 
as well. Because side effects were not clearly associated with exenatide-ER in the present study 
and none was moderate to severe or long-lasting, we assume that the GLP-1 analogue can be 
safely used in diabetic cats. Of note, injection-site irritation as well as nodular, eosinophil-rich, 
granulomatous panniculitis at the injection site of exenatide have been described in humans.22,23 
To date, dermatologic irritation has not been reported in cats.10,12,14 Skin nodules that were 
identified in 1 of our diabetic cats were likely unrelated to exenatide-ER injections. The lesions 
were non-pruritic, 5 to 10 cm from the injection site and diagnosed histologically as histiocytic 
panniculitis, all of which suggest that exenatide-ER was not the cause. 
There have been concerns about incretin-based therapies and pancreatitis in humans, but studies 
did not find a significant association.24,25 The Food and Drug Administration and the European 
Medicines Agency recently stated that it is currently unclear whether there is a causal relationship 
between incretin-based drugs and pancreatitis.26 To our knowledge, a possible association 
between incretin-based therapy and pancreatitis in cats has not been investigated. Our previous 
research showed that many cats with DM may have subclinical pancreatitis.27 In the present 
study, some cats treated with exenatide-ER had clinical signs that included reduced appetite and 
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vomiting; however, it is not known whether this was because of the drug, pancreatitis or some 
other cause. In the exenatide-ER group, only 1 (8.3%) cat with normal baseline Spec fPL and 
DGGR-lipase concentrations had an increase in Spec fPL concentration during treatment, 
possibly suggesting drug-induced pancreatitis. We cannot exclude the possibility that exenatide-
ER increases the risk of pancreatic adverse effects in some diabetic cats, but further studies are 
required to clarify this. 
An increase in creatinine concentration has been reported in some humans treated with GLP-1 
analogues, which suggests that renal failure may occur or worsen during therapy. Based on this 
information, exenatide treatment is not recommended, particularly in patients with severe renal 
impairment.h In the present study, the increase in serum creatinine did not differ between the two 
groups. In most cats, creatinine concentrations stayed within the normal range. However, diabetic 
cats with relevant kidney disease were excluded; it is therefore possible that an increase in 
creatinine concentration would have occurred if diabetic cats with renal failure had been 
included. This finding might be explained by the fact that body weight, and possibly muscle mass 
along with creatinine, augmented in most cats during insulin treatment. 
An investigation of type 2 diabetic humans receiving insulin glargine and short-acting exenatide 
or placebo showed that the incidence of hypoglycemic episodes was similar in both groups.28 In 
healthy cats treated with exenatide-ER biochemical hypoglycemia was seen, whereas clinical 
hypoglycemia did not occur.12 Similarly, in the present study biochemical hypoglycemia was a 
common finding, however there was no difference between the 2 groups. Clinical hypoglycemia 
was seen in 2 cats of the exenatide-ER group. As these were 2 single episodes which were short-
lived, we hypothesize that exenatide-ER is safe when used in conjunction with insulin to treat 
diabetic cats. 
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Compared with the results of other studies of diabetic cats, the remission rates in the present 
investigation were relatively low in both groups. Other studies have followed diabetic cats for 
longer periods of time (e.g. 6 months) than our study (4 months),29,30 and it is therefore possible 
that more cats would have achieved remission if the study had been longer. In addition, it is 
known that the rate of remission is higher if diabetic cats have received corticosteroids before 
diagnosis of DM.18 In the present study cats with prior corticosteroid administration were not 
used, whereas in one other study with high remission rate those cats were included.31 This 
difference in selection criteria may explain at least in part the different remission rates. 
Furthermore, our definition of remission was the maintenance of euglycemia without insulin 
treatment for 4 weeks, whereas an other study defined remission as 2 weeks of euglycemia 
without insulin.31 If we had used this latter definition, there would have been 2 additional cats in 
remission in the exenatide-ER group, and thus the rate of remission would have increased from 
40% to 53.3% (8 of 15 cats). 
In humans with type 2 DM, exenatide-ER once weekly was superior to other GLP-1 analogues in 
controlling blood glucose concentrations.5,6 Exenatide-ER, in addition to oral antidiabetic agents, 
was also able to provide better glycemic control than insulin detemir.32 The present study shows 
that the percentage of cats that achieved good metabolic control was higher in the exenatide-ER 
group than the placebo group (93.3% vs. 66.7%, respectively) when cats in remission were 
grouped together with those with good metabolic control. The difference between groups was not 
significant because of the relatively low number of cats, but significance (P<0.05) would have 
been achieved if there had been 15 instead of 14 cats with good metabolic control or remission in 
the exenatide-ER group.  
In humans with type 2 DM, treatment with GLP-1 analogues is associated with weight loss 
whereas insulin glargine therapy is associated with weight gain.32 Weight loss was described in 
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healthy cats during treatment with exenatide or liraglutide.11,13 In the present study, a significant 
weight gain and increase in BCS were seen in cats of the placebo group, likely due to the 
anabolic effect of insulin therapy; however, the increase was not significant in the exenatide-ER 
group. Prevention of weight gain is advised in diabetic cats with a high BCS, while weight gain 
to normalize body condition is preferable for diabetic cats with a low BCS. In general, exenatide-
ER administration increased BCS in those with low baseline BCS, but did not increase BCS in 
cats with high baseline BCS. In humans treated with GLP-1 analogues, weight control can be 
attributed to a reduction in appetite because of increased satiation and a delay in gastric 
emptying.20,33  
This study had some limitations including the relatively low number of cats; significant 
differences for rates of remission and good metabolic control may have been seen in a larger 
number of diabetic cats. Furthermore, the follow-up period was set at 4 months and it is possible 
that more cats would have achieved remission or good metabolic control if a longer study period 
had been chosen. 
In summary, exenatide-ER is not associated with local or systemic side effects and can be safely 
used in diabetic cats. Exenatide-ER treatment does not result in a significant increase in body 
weight and may improve the rate of remission and metabolic control, although further studies 
using large cohorts are required. 
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Footnotes 
ahttp://vetmed.tamu.edu/gilab/service/assays/pli 
bNationWide, Specialist Laboratories, Cambridge, England 
cLantus, Sanofi Aventis, Meyrin, Switzerland  
dDM Purina Veterinary Diets, Medical Solution, Steinhausen, Switzerland 
eBydureon, Amylin Pharmaceuticals, San Diego, CA 
f
Body condition chart (cat); Nestlé Purina, St. Louis, MO 
gSPSS 18.0, SPSS, Chicago, IL 
hhttp://www.fda.gov/safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts
/ucm188703.htm 
23 
 
References 
1. Buteau J, Foisy S, Joly E, et al. Glucagon-like peptide 1 induces pancreatic β-cell 
proliferation via transactivation of the epidermal growth factor receptor. Diabetes 2003;52:124-
132. 
2. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 
2007;132:2131-2157. 
3. Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: Properties, functions, and 
clinical implications. Am J Med 2011;124:3-18. 
4. Bergenstal RM, Wysham C, MacConell L, et al. Efficacy and safety of exenatide once 
weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 
diabetes (DURATION-2): A randomised trial. Lancet 2010;376:431-439. 
5. Blevins T, Pullman J, Malloy J, et al. DURATION-5: Exenatide once weekly resulted in 
greater improvements in glycemic control compared with exenatide twice daily in patients with 
type 2 diabetes. J Clin Endocrinol Metab 2011;96:1301-1310. 
6. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the 
treatment of type 2 diabetes: A randomised, open-label, non-inferiority study. Lancet 
2008;372:1240-1250. 
7. Hoenig M, Jordan ET, Ferguson DC, et al. Oral glucose leads to a differential response in 
glucose, insulin, and GLP-1 in lean versus obese cats. Domest Anim Endocrinol 2010;38:95-102. 
8. Furrer D, Kaufmann K, Tschuor F, et al. The dipeptidyl peptidase IV inhibitor NVP-
DPP728 reduces plasma glucagon concentration in cats. Vet J 2010;183:355-357. 
9. Nishii N, Takashima S, Iguchi A, et al. Effects of sitagliptin on plasma incretin 
concentrations after glucose administration through an esophagostomy tube or feeding in healthy 
cats. Domest Anim Endocrinol 2014;49:14-19. 
24 
 
10. Gilor C, Graves TK, Gilor S, et al. The GLP-1 mimetic exenatide potentiates insulin 
secretion in healthy cats. Domest Anim Endocrinol 2011;41:42-49. 
11. Seyfert TM, Brunker JD, Maxwell LK, et al. Effects of a glucagon-like peptide-1 mimetic 
(exenatide) in healthy cats. Intern J Appl Res Vet Med 2012;10:147-156. 
12. Rudinsky AJ, Adin CA, Borin-Crivellenti S, et al. Pharmacology of the glucagon-like 
peptide-1 analog exenatide extended-release in healthy cats. Domest Anim Endocrinol 
2015;51:78-85. 
13. Hall MJ, Adin CA, Borin-Crivellenti S, et al. Pharmacokinetics and pharmacodynamics of 
the glucagon-like peptide-1 analog liraglutide in healthy cats. Domest Anim Endocrinol 
2015;51:114-121. 
14. Padrutt I, Lutz TA, Reusch CE, et al. Effects of the glucagon-like peptide-1 (GLP-1) 
analogues exenatide, exenatide extended-release, and of the dipeptidylpeptidase-4 (DPP-4) 
inhibitor sitagliptin on glucose metabolism in healthy cats. Res Vet Sci 2015;99:23-29. 
15. Tschuor F, Zini E, Schellenberg S, et al. Remission of diabetes mellitus in cats cannot be 
predicted by the arginine stimulation test. J Vet Intern Med 2011;25:83-89. 
16. Oppliger S, Hartnack S, Riond B, et al. Agreement of the serum Spec fPLTM and 1,2-o-
dilauryl-rac-glycero-3-glutaric acid-(6’-methylresorufin) ester lipase assay for the determination 
of serum lipase in cats with suspicion of pancreatitis. J Vet Intern Med 2013;27:1077-1082. 
17. Zini E, Moretti S, Tschuor F, et al. Evaluation of a new portable glucose meter designed 
for the use in cats. Schweizer Archiv für Tierheilkunde 2009;15:448-51. 
18. Reusch CE. Feline diabetes mellitus. In: Feldman EC, Nelson RW, Reusch CE, Scott-
Moncrieff JC, eds. Textbook of Canine and Feline Endocrinology, 4th ed. St. Louis, MO: 
Saunders; 2015:258-314. 
 
25 
 
19. Sieber-Ruckstuhl NS, Kley S, Tschuor F, et al. Remission of diabetes mellitus in cats with 
diabetic ketoacidosis. J Vet Intern Med 2008;22:1326-1332. 
20. Campbell RK. Clarifying the role of incretin-based therapies in the treatment of type 2 
diabetes mellitus. Clin Ther 2011;33:511-527. 
21. Näslund E, Gutniak M, Skogar S, et al. Glucagon-like peptide 1 increases the period of 
postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr 1998;68:525-530. 
22. Boysen NC, Stone MS. Eosinophil-rich granulomatous panniculitis caused by exenatide 
injection. J Cutan Pathol 2014;41:63-65. 
23. Shan SJ, Guo Y. Exenatide-induced eosinophilic sclerosing lipogranuloma at the injection 
site. Am J Dermatopathol 2014;36:510-512. 
24. Romley JA, Goldman DP, Solomon M, et al. Exenatide therapy and the risk of pancreatitis 
and pancreatic cancer in a privately insured population. Diabetes Technol Ther 2012;14:904-911. 
25. Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported 
with exenatide and liraglutide: Acute pancreatitis and cancer. Diabetes Res Clin Pract 
2012;98:271-284. 
26. Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs – FDA and 
EMA assessment. N Engl J Med 2014;370:794-797 
27. Zini E, Hafner M, Kook P, et al. Longitudinal evaluation of serum pancreatic enzymes and 
ultrasonographic findings in diabetic cats without clinically relevant pancreatitis at diagnosis. J 
Vet Intern Med 2015;29:589-596. 
28. Buse JB, Bergenstal RM, Glass LC, et al. Use of twice-daily exenatide in basal insulin-
treated patients with type 2 diabetes: A randomized, controlled trial. Ann Intern Med 
2011;154:103-112. 
26 
 
29. Zini E, Hafner M, Osto M, et al. Predictors of clinical remission in cats with diabetes 
mellitus. J Vet Intern Med 2010;24:1314-1321. 
30. Hafner M, Dietiker-Moretti S, Kaufmann K, et al. Intensive intravenous infusion of insulin 
in diabetic cats. J Vet Intern Med 2014;28:1753-1759. 
31. Roomp K, Rand J. Intensive blood glucose control is safe and effective in diabetic cats 
using home monitoring and treatment with glargine. J Feline Med Surg 2009;11:668-682. 
32. Davies M, Heller S, Sreenan S, et al. Once-weekly exenatide versus once- or twice-daily 
insulin detemir: Randomized, open-label, clinical trial of efficacy and safety in patients with type 
2 diabetes treated with metformin alone or in combination with sulfonylureas. Diabetes Care 
2013;36:1368-1376. 
33. Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists 
and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705. 
27 
 
Tables 
Table 1. Blood and urine examinations at baseline and during all follow-up examinations. 
Blood analysis Baseline Follow-up 
Complete blood cell count + + 
Biochemical profile + + 
Fructosamine + + 
T4 +  
Spec fPL + + 
IGF-1 +  
Urinalysis with UPC and culture +  
UPC, urine protein-to-creatinine ratio 
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Table 2. Criteria used to define remission and good metabolic control in cats with DM.15,18,19 
Endpoint Clinical signs Fructosamine (µmol/L) Glucose (mg/dL) Insulin treatment 
Remission absent <350  72-162 No (for ≥4 weeks) 
Good metabolic control absent 350-450 80-270 Yes 
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Table 3. Signalment of diabetic cats and pretreatment with antidiabetic medications before 
inclusion in the study.  
Animals Exenatide-ER (n=15) Placebo (n=15) P-value 
Age, range and median in years 4.3-14.0 (9.3) 2.6-15.0 (10) 0.547 
Body weight, range and median in kg 4.4-7.4 (5.3) 2.7-8.3 (4.5) 0.110 
    
Domestic short- or longhair 12 (80%) 14 (93.3%) 
0.598 
Purebred 3 (20%) 1 (6.7%) 
    
Neutered male 9 (60%) 5 (33.3%) 
0.143 Intact male 1 (6.7%) 0 (0%) 
Spayed female 5 (33.3%) 10 (66.7%) 
    
Pretreatment* 8 (53.3%) 10 (66.7%) 0.710 
*antidiabetic medications received before inclusion. 
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Table 4. Type, time of occurrence and duration of side effects in diabetic cats treated with exenatide-ER or placebo. 
 Exenatide-ER  Placebo  P-value 
Side effect Cats (n=15) Dpi* Between week  Cats (n=15) Dpi* Between week   
Reduced appetite 9 (60%) 1 to 3 1 to 10  3 (20%) 0 to 7 2 to 6  0.060 
Vomiting 8 (53.3%) 1 to 4 0 to 15  6 (40%) 1 to 6 0 to 16  0.715 
Diarrhea 1 (6.7%) 6 1 to 14  3 (20%) 1 to 3 1 to 14  0.598 
Increased sleeping 5 (33.3%) 1-3 1 to 6  1 (6.7%) 1-3 0 to 6  0.169 
Hiding in dark areas 3 (20%) 0 to 3 0 to 3  1 (6.7%) 1 9  0.598 
* Dpi, days post injection.
31 
   
Table 5. Laboratory results and blood pressure measurements at baseline in diabetic cats 
treated with exenatide-ER vs. placebo. Range and median values are given. 
Parameter Exenatide-ER Placebo Reference interval P-value 
Hematocrit (%) 29-47 (37) 25-47 (34) 33-45 0.254 
Leukocytes (103/µL) 3.2-20.5 (8.9) 4.8-22.1 (10.8) 4.6-12.8 0.165 
Platelets (103/µL) 207-525 (340) 156-672 (347) 180-680 0.923 
Glucose (mg/dL) 101-810 (392) 70-536 (428) 72-162 0.543 
Fructosamine (µmol/L) 402-883 (620) 438-878 (582) 202-340 0.604 
Cholesterol (mg/dL) 132-565 (256) 112-662 (267) 101-263 1.000 
Triglycerides (mg/dL) 26-350 (79) 35-3478 (70) 26-114 0.537 
Total protein (g/dL) 6.4-11.4 (7.4) 6.3-8.3 (7.4) 6.4-8.0 0.405 
Albumin (g/dL) 3.1-4.1 (3.6) 2.7-4.4 (3.5) 3.0-4.0 0.884 
Urea (mg/dL) 17.6-52.1 (30.0) 21.6-37.2 (29.1) 20.7-35.3 0.494 
Creatinine (mg/dL) 0.9-1.9 (1.1) 0.6-1.7 (1.2) 1.1-1.8 0.527 
Sodium (mEq/L) 145-165 (157) 145-165 (158) 158-165 0.967 
Chloride (mEq/L) 99-126 (118) 105-121 (116) 121-131 0.220 
Potassium (mEq/L) 4.3-5.4 (4.7) 3.4-5.9 (4.8) 3.8-5.4 0.755 
Phosphorus (mg/dL) 2.7-6.5 (4.5) 2.5-5.0 (4.2) 2.8-5.6 0.130 
Calcium (mg/dL) 1.1-11.9 (10.3) 9.3-11.9 (10.4) 9.6-11.2 0.967 
Bilirubin (mg/dL) 0.02-0.43 (0.09) 0.01-0.43 (0.08) 0-0.2 0.747 
ALP (U/L) 30-112 (50) 32-92 (49) 16-43 0.975 
ALAT (U/L) 34-424 (76) 33-379 (87) 34-98 0.709 
ASAT (U/L) 19-215 (29) 17-133 (41) 19-44 0.184 
DGGR-Lipase (U/L) 11-92 (25) 13-48 (23) 8-26 0.734 
Spec fPL (µg/L) 0.6-41.8 (2.2) 0.6-16.8 (3.0) >5.3 0.878 
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T4 (µg/L) 0.7-2.4 (1.5) 0.5-1.8 (1.4) <3.5 0.361 
IGF-1 (ng/mL) 227-1163 (372) 167-1041 (405) <1000 0.408 
UPC 0.08-1.04 (0.22) 0.1-1.2 (0.2) ≤0.40 0.913 
SAP (mm Hg) 96-224 (144) 85-189 (145) 80-160 0.573 
ALP, alkaline phosphatase; ALAT, alanine aminotransferase; ASAT, aspartate 
aminotransferase; UPC, urine protein-to-creatinine ratio; SAP, Systolic arterial pressure. 
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Table 6. Body condition score in diabetic cats treated with exenatide-ER or placebo at 
baseline (week 0) and at week 16. Within each group, cats are divided according to their body 
weight at week 16, which is compared to week 0 and reported as increased, decreased or no 
change. 
 
 
 BCS (1-9) 
Group Body weight after 16 weeks Number of cats Week 0 Week 16 
Exenatide-ER Increased  2 4 5 
  1 4 6 
  2 5 5 
  2 5 6 
  1 7 8 
 Decreased  2 4 4 
  2 5 5 
  1 6 6 
  1 6 5 
 No change 1 5 5 
Placebo Increased  1 3 4 
  1 3 5 
  3 4 5 
  3 5 6 
  2 6 6 
  1 6 8 
  1 7 8 
  1 7 9 
 Decreased 2 5 5 
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Table 7. Onset of remission in diabetic cats treated with exenatide-ER or placebo (P=0.167). 
Onset of remission 
Exenatide-ER 
(number of cats) 
Placebo 
(number of cats) 
0-6 weeks after discharge 0 0 
7-10 weeks after discharge 2 3 
11-16 weeks after discharge 4 0 
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Figures 
Figure 1. Number of diabetic cats with episodes of hypoglycemia during the 16-week study 
period. 
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Figure 2. Serum concentration of Spec fPL (A) and DGGR-lipase (B) in exenatide-ER- and 
placebo-treated cats during the 16-week study period. Medians are shown. Dashed lines 
identify the reference interval. There were no differences between the groups.  
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Figure 3. Dot plots of median insulin dose administered per kg body weight per day in cats 
receiving exenatide-ER or placebo. Horizontal lines mark the group medians. 
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Figure 4. Body weight of cats of the exenatide-ER and placebo groups at baseline and week 
16. Horizontal lines indicate the median body weight. 
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